Third Harmonic Bio plans a Phase 2 trial for THB335 in chronic spontaneous urticaria and will reduce its workforce by 50% ...

Bio, Inc. (NASDAQ:THRD), a clinical-stage biopharmaceutical company with a market capitalization of $209.5 million, today announced positive Phase 1 clinical trial results for its drug candidate ...

Third Harmonic Bio shares dived 35% in premarket trading amid a broader evaluation of THB335. Shares were trading around $3.03. The stock is down 50% over the last year.

Third Harmonic Bio (THRD) announced results from its Phase 1 single and multiple ascending dose clinical trial of THB335 in healthy volunteers.

The MAD cohort also saw adverse events such as hair loss and reductions in hemoglobin and neutrophil counts. These side ...

(RTTNews) - Third Harmonic Bio, Inc. (THRD), a clinical-stage biopharmaceutical company, on Tuesday announced promising results from its Phase 1 clinical trial of THB335, a potent and selective ...

In parallel with THB335 Phase 2 readiness activities, Third Harmonic Bio (THRD) is initiating a process to identify opportunities to maximize ...

These data are expected to support the advancement of THB335 into a Phase 2 clinical trial in chronic spontaneous urticaria (CSU). The Company is initiating a strategic review process to run in ...

On Tuesday, Third Harmonic Bio, Inc. (NASDAQ:THRD) revealed results from its Phase 1 single and multiple ascending dose (SAD/MAD) trial of THB335 in healthy volunteers. The company says the data ...

These data are expected to support the advancement of THB335 into a Phase 2 clinical trial in chronic spontaneous urticaria (CSU). The Company is initiating a strategic review process to run in ...